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ABSTRACT
Objective: To identify and highlight challenges related to informed consent process 
for clinical trials in sub-Saharan Africa.
Data sources: Published original research ﬁndings and reviews in the English literature, 
together with anecdotal information from our current professional experiences with 
clinical trials.
Design: Review of peer-reviewed articles.
Data extraction: Online searches were done and requests for reprints from corresponding 
authors and institutional subscription.
Data synthesis: Information categorised accordingly.
Results: Informed consent for clinical trials conducted in sub-Saharan Africa (SSA) is 
not always “truly informed” or “truly voluntary”. Guidelines for obtaining informed 
consent are often difﬁcult to implement because of low literacy levels, socio-economic 
and cultural factors. The local ethics committees,  whose role is critical in informed 
consent, are weak, ill-equipped or non-existent in some countries. Many participants 
may have incomplete understanding of the various aspects of the clinical trials due to 
language barriers, the way information is disclosed or terms used for informed consent 
documents. In some settings, clinical trials are the only access to health care services 
for the local population. Further, participants may enroll with perceived notion of 
cure of their conditions, for monetary or material beneﬁts.
Conclusions: There is need for national guidelines on clinical research including ethics 
review, compensation of subjects, requirements for research investigators, facilities 
and ethics committees as well as budgetary allocation. These guidelines must not only 
address speciﬁc and unique local circumstances but also meet minimum international 
clinical research standards. Local bioethics and research capacity should be developed 
and strengthened with research sponsors contributing towards this. Local research is 
needed on the validity and reliability of informed consent for clinical trials and factors 
inﬂuencing that in different socio-cultural settings in SSA.
INTRODUCTION
Clinical trials are used to determine the efﬁcacy 
and safety of new pharmaceutical products or 
treatment procedures. Randomised and controlled 
clinical trials (RCTs) are considered the safest and 
fastest means of identifying treatments that work 
in human beings. The goal of a clinical trial is to 
answer speciﬁc questions about drugs, vaccines, 
new devices or therapies or therapeutic approaches 
of known treatments (1).
 Clinical trials are becoming increasingly 
necessary because of emergence of new diseases 
afﬂicting mankind such as HIV/AIDS; resistance to 
standard drugs e.g. antimalarials and antibiotics; the 
need to improve the quality and prolong the lives of 
individuals with chronic and debilitating conditions 
such as cancer, diabetes and hypertension and 
congenital anomalies/birth defects. There is also an 
increasing demand from the public due to heightened 
awareness, for prevention and treatment of common 
and debilitating conditions. Equally important are 
social and economic concerns for communicable and 
chronic diseases.
 Ideas about clinical trials may be originated 
by scientists including health professionals based 
on their clinical and public health experiences, the 
pharmaceutical industries that wish to market their 
products, international organisations, or governmental 
agencies such as regulatory authorities.
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 As clinical trials are costly and resource-intensive 
and take long to realise their goals, it is imperative 
that the results thereof are not only credible but also 
reliable. They must not only show that the drug 
works and is safe for human beings but identify 
the ideal conditions for its use as well as potential 
adverse effects (1-4). They need to be conducted in 
diverse settings and communities, especially those 
most affected by the condition under study. However 
due to cost constraints, representative countries 
and localities are selected to represent the wider 
community for which it will be used. It is assumed 
that the data from these can be pooled together and 
analysed and the results thereof generalised (5,6). 
To this end internationally acceptable standards for 
conducting clinical trials must be adhered to at all 
stages of a study. 
 Good clinical practice (GCP) is an international 
ethical and scientiﬁc quality standard for the design, 
conduct, performance, monitoring, auditing, 
recording, analysis and reporting of clinical trials, 
that provides assurance that the data and reported 
results are credible and accurate and that the rights 
and integrity of trial subjects are protected (6). Study 
subjects should only include eligible participants, who 
are identiﬁed through the screening and consenting 
process, an essential aspect for a successful clinical 
trial. The individual’s consent must be truly informed 
and truly voluntary (7,8).
 There are concerns whether informed consent by 
study participants especially in the developing world 
are genuinely informed and voluntary (9-11). There 
is very limited literature on informed consent and 
its role in clinical trials in sub-Saharan Africa. With 
internationalisation of clinical trials and the majority 
of speciﬁc types such as those on HIV-prevention 
taking place in the region, the concerns on informed 
consent are even more critical.
 Clinical trials use relatively complex and detailed 
patient information and informed consent documents, 
which are written in academic language and that of 
the sponsor’s country of origin. Although these are 
translated into national or local languages of the 
host countries, individuals who are educationally 
disadvantaged as is the case in most of SSA rural areas 
may have problems comprehending the disclosures 
(9-13). The fact that a majority of the clinical trials 
take place within public health facilities, participants 
may not be able to discern between routine care and 
research (14). Cognisant of the special situations of 
developing countries, the CIOMS issued guidelines on 
how these ethical principles should guide biomedical 
research involving human subjects (5).
 Making a decision to participate in a clinical trial 
involves understanding of the potential risks and 
beneﬁts as well as ones rights and responsibilities. This 
is said to have cognitive, emotional, motivational and 
value-based components (10). It has been argued that 
the decision to participate is often made before and 
independent of the disclosed technical information 
during counselling and consenting process (15), and 
that personal and cultural values play a major role 
in this.
 This article highlights challenges related 
to informed consent from our experiences in 
participating in various clinical trials in the SSA 
region. It proposes strategies to address some of the 
shortcomings.
INFORMED CONSENT
Definition: Informed consent is an autonomous 
authorisation by an individual for involvement in 
a research study or to receive medical care and the 
documentation thereof (15). It is fundamental to 
the ethical conduct of a clinical trial and a critical 
component of the process thereof. Through the 
informed consent process, the potential study subjects 
learn about the important facts related to the clinical 
trial which enable them to make informed decision 
to participate or not. It is essential for protecting 
the rights and ensuring the safety and privacy of 
potential study participants. The Belmont Report 
(1979) deﬁnes informed consent as essential to the 
principle of respect (3). 
Origins: The origin of informed consent is credited to 
the Nuremberg Code (1947), which made voluntary 
consent a requirement in clinical research studies (8). 
The Code together with the Declaration of Helsinki 
(1978) which focused on the obligations of the 
investigators to research subjects (4) are considered the 
mainstay of ethical guidelines for research involving 
human subjects. Informed consent is now enshrined 
in the WHO International Ethical Guidelines for 




Key components of informed consent
• Full disclosure – on the purpose of the study, 
its duration, the related risks and beneﬁts and 
alternative therapeutic options
• Information – should be in writing in a form that 
is easily comprehensible and the subject must 
understand fully the information given
• The consent –  must be obtained freely and the 
subject should be free to refuse or withdraw at 
any time without prejudice
• The subject – must be competent to give 
consent. 
Informed consent is an ethical principle of 
autonomy and self-determination (16). The ethics 
March 2009 EAST AFRICAN MEDICAL JOURNAL   135
committee of the sponsoring country and that of 
host country must review the research protocols 
for among other things protection of subjects’ 
rights, safety and well-being. The research team 
should be competent and knowledgeable on inter-
personal communication. The interaction between 
investigators and subjects must be continuous 
throughout the period of the study and beyond 
(6, 15).
 Protection of trial subjects is the primary 
concern of all parties involved in the conduct of 
a clinical trial and review of the protocol. The 
principle of informed consent requires that health 
professionals or research investigators explain to the 
patients or subjects what is involved and ensures 
one understands before consenting. This must be 
done prior to any procedures (4-6). 
 The doctrine of informed consent dictates that 
research participants should enter into a research 
study voluntarily and with adequate information. 
Informed consent is given by a competent individual 
who has received the necessary information, who has 
adequately understood the information and who after 
considering the information has arrived at a decision 
without having been subjected to coercion, undue 
inﬂuence, inducement or intimidation. It is premised 
on the notion that individuals have the right and the 
ability to make decisions in their own interest and to 
act upon them (17). It protects the individuals freedom 
of choice and respects the individual‘s autonomy.
Challenges:
Table 2
Constraints in the application of ethical   principles in less-developed countries (LDC’s)
Ethical guideline 
Review of research protocols by ethics committee/
institutional review boards
Reasonable risk-beneﬁt ratio
Adequate plans for the care and compensation 
of participants for injuries directly related to 
the research
Individual informed-consent from all 
participants
Equal regard for all participants
Equitable distribution of the burden and beneﬁts 
of research 
Constraint to application in LDC’s
Lack of experienced, independent EC/IRB’s
Assessment of risk-beneﬁt ratio may be biased 
by prevalence of related clinical conditions
Participants may not be aware they are entitled 
to compensation
Participants may not report adverse events or 
injuries
Low literacy levels, social, economic and cultural 
constraints may prevent informed independent 
consent
Cultural or political restrictions to participation 
of members of certain social groups, or based 
on gender
I n c e n t i v e s  m a y  d r a w  p a r t i c i p a n t s 
disproportionately from the poorest segments 
of the population
The individuals may not afford the drugs when 
approved and registered due to cost
Bias towards more urban or peri-urban areas 
for ease of access by research team
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i) Ethics Committees and Institutional Review 
Boards: Approval of research protocol by an ethics 
committee or institutional review board (EC/IRB) 
is a requirement for any clinical trial whether 
international or local (4-6). 
 These are independent bodies consisting 
of health care professionals and non-medical 
members, whose responsibility is to verify that the 
human rights, safety, integrity and well-being of 
human subjects participating in medical research 
are protected and to consider the general ethics of 
the trial thereby providing public assurance of that 
protection (4,6). They are supposed to review the 
research protocol, the informed consent documents, 
suitability of investigators involved in the trial and 
adequacy of the facilities to be used for the various 
aspects of the trial. They should also receive and 
appraise progress reports from the investigators as 
well as any new information related to the study from 
the investigators as it may arise. One of the main 
functions of the EC/IRB is to ensure that potential 
study subjects are adequately informed about the 
clinical trial, the beneﬁts and risks thereof, their 
rights to withdrawal at any time and alternative 
treatment options (18, 19).
 There have been concerns about the capacity 
for ethics review of clinical trials. It is acknowledged 
that this capacity is not universal and the developing 
countries such as those in SSA have major limitations 
in this regard (19 -21).  Sometimes institutional review 
boards from developed sponsor countries review 
protocols that will be conducted in one or more host 
developing countries. Many of the members on these 
boards may not be familiar with the host country’s 
culture, language, social and ethical norms, level of 
health care and other factors essential for a thorough 
ethical review of the protocols. In majority if not all 
international clinical trials, the EC of the country 
of origin and the host have to review and approve 
the protocols. In some cases there are several bodies 
within the country that have to review a protocol. 
Unless the requisites are harmonized, there may be 
conﬂicting decisions. This is more critical in multi-
country or multi-center trials.
  There has been limited research examining 
procedures, strengths and challenges facing ethics 
committees in developing countries.  Many EC/IRBs 
especially in SSA have difﬁculties in recruiting and 
retaining community members who have sufﬁcient 
time, interest and education to comprehend the 
complex scientific protocols they review. They 
may therefore approve trials which may expose 
participants to undue harm. Secondly they may not 
be able to critically review the informed consent 
documents and procedures to ensure safety of the 
participants. From the experience of one of us who 
had the privilege of serving on an institutional review 
board in one country in SSA for a period of six years, 
it is difﬁcult to get capable non-medical members as 
required to serve on ECs, and those who agree often 
miss committee meetings for one reason or another 
and when they participate their contribution is often 
insigniﬁcant. 
 Some members of IRBs demand or expect to be 
remunerated for their time and effort. If they don’t 
get paid their participation may be compromised. 
There are no guidelines as to whether they should 
be paid and how much. Secondly if and when they 
get paid as it happened in the committee referred 
to above, what may be considered adequate by one 
may be inadequate or too much for another which 
may exert an “undue inducement” on his/her level 
of commitment.
 There may be conﬂict of interest if a member of the 
EC/IRB has ﬁnancial connection with the sponsoring 
organisation, or the manufacturer, or who may gain 
ﬁnancially from the results of the study. He/she may 
approve a protocol without considering the rights 
of the subjects. Others may inﬂuence enrollment of 
subjects who are relatives or even themselves into 
the clinical trials. 
ii) The research team:  The composition and quality 
of the research team is one of the key determinants 
for a successful clinical trial. In most SSA countries 
the principal investigator (PI) who is the overall in 
charge of the clinical trial is a physician, specialist 
in the discipline under which the study is being 
conducted. The day to day management of the study 
including screening, counselling and consenting 
of potential study subjects is handled by either 
clinical ofﬁcers or nurses. These cadres have little 
or no training on research methodology and ethics 
and may have limited knowledge of the health 
condition under study. They may therefore not be 
able to provide adequate information especially in 
response to subjects’ questions, thus compromising 
their informed consent. Some research investigators 
are foreigners and may not know the social, cultural 
or economic context of the host countries and may not 
have personal interest in the health care of the local 
community. The principal investigator is responsible 
for ensuring that information in the consent form and 
other related documents is accurately explained to and 
apparently understood by the subjects. However there 
are no speciﬁc guidance or standards for assessing 
this “explanation” and “understanding”. 
 Secondly, if their remuneration is pegged on the 
number of eligible participants recruited, which is the 
case in most studies, they may take short cuts and not 
provide full disclosure especially on risks involved 
or available alternative treatment options. They may 
stress on the beneﬁts of the study, thus coercing the 
subjects to enroll in the study in order to realise the 
numbers (22, 23). 
 Most of the clinical trials in SSA are conducted 
within public health facilities. Members of the 
research team are usually staff working in the same 
facilities and therefore well known to the potential 
subjects or members of their families. The subjects 
may therefore consent because of “trust” in the 
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health team (24), a feeling that they are expected 
to participate by the health team (25), or for fear 
that if they do not participate they may experience 
problems later on when they seek health care at the 
same facility (26). In a study by Karim et al (11) in 
South Africa, 88% of the participants felt that they 
were compelled to participate in the clinical trial 
while 28% thought if they refused to participate it 
may compromise their care.
 The physician may have conﬂict of interest as 
they may have difﬁculty distinguishing between 
their primary goal of treating patients and that of a 
researcher i.e. to test scientiﬁc hypothesis (26). They 
may also want their patients enrolled into the study 
and inﬂuence their participation. This may inﬂuence 
who gets enrolled. Likewise, physicians with shares or 
other ﬁnancial interests in the study results may have 
conﬂict of interest and this may impact negatively on 
the informed consent process as they will put their 
personal gains before subjects’ safety (27). A researcher 
in an academic institution may have conﬂict of interest 
because he/she has to discern what is good for the 
current patient, future patients i.e. the good of society, 
the institution and his/her career development (25). 
The research team may withhold key information or 
not follow good clinical practice guidelines if there 
is no proper oversight by ethics committee. 
iii) Comprehension and retention of disclosed information: 
Consent for clinical trials is considered “informed” 
when the subjects giving it understand the purpose 
and nature of the study, what is expected of them, 
and the potential beneﬁts and risks resulting from 
the study (4-6). There are concerns whether clinical 
trial subjects do really understand enough about 
the study before consenting. A number of studies in 
industrialised countries have shown the existence 
of gaps in the information provided and the 
understanding by study subjects (9-13). That being the 
case, it is not far-fetched to postulate that the scenario 
is even worse in SSA, cognisant of the high poverty 
and low literacy levels and poor access to quality 
health care services, which make them vulnerable 
to exploitation for research purposes. From our 
experience this is a fairly common phenomenon.
 Clinical trials conducted in SSA originate from 
developed countries and usually utilise relatively 
complex and detailed patient information documents 
written in academic language, sometimes imported 
from the country of the study origin. Although IRBs 
insist that these be translated into locally understood 
or spoken languages, some words do not have their 
equivalence in local languages. Where the IRB does 
not insist on translation into a local language, the 
researchers may administer the informed consent in a 
foreign language. In a study in one country in Africa 
where less than 25% of the population understand 
or speak English we were shocked to note that the 
research team was disclosing the information and 
consent process in English and only asking the 
subjects to append their signatures or thumb prints 
to the consent forms which were also in English. 
As a result study subjects who are educationally 
challenged may have problems comprehending the 
disclosed information. The length and complexity 
of the informed consent documents and related 
subject information may impact negatively on a 
subject’s understanding of the clinical trial related 
information (29). The way the information is packaged 
and presented such as presenting risks or beneﬁts in 
percentages, may not be well appreciated especially 
by the educationally disadvantaged individuals.
 Subjects consent to participating in clinical 
trials is a basic ethical and legal pre-condition to 
conscientious medical practice and the ethical 
principal of respect for person’s autonomy requires 
that they understand the accessible treatment options 
among which they may choose (30). The decision to 
do either can only be genuine and valid if it is based 
on adequate information. The major challenge is 
how much information should be disclosed to be 
considered “enough” for appropriate decision, but 
at the same time not “too much” to frighten subjects 
either from participating or into compliance!
iii) Therapeutic misconception: At times study 
subjects fail to appreciate the distinction between 
the imperatives of clinical trials and those of routine 
medical care, thus attributing therapeutic intent to 
research procedures. This is referred to “therapeutic 
misconception” (31). The subjects may not appreciate 
the implications of their decisions. They may expect 
personalised care, which is part of routine medical 
care but not necessarily part of clinical trials.
 Therapeutic misconception is a serious problem 
for the informed consent process in clinical trials. 
It may arise because of patients’ faith in the health 
care providers and belief that they will do nothing 
that is not in their best interest, or may be as a result 
of the disclosed information by the research team 
which may reinforce a subject’s predilection for, or 
misinterpretation of the information so disclosed 
(14). Benson et al (32) observed that some researchers 
may underscore the therapeutic potential of the 
studies, thus inﬂuencing potential subjects’ decision 
to participate.
 Subjects who are also patients who do not 
adequately appreciate the purpose and methods of 
research studies are ill-equipped to evaluate related 
beneﬁts and risks and fail to recognise how personal 
care may be compromised by research procedures, 
such as randomisation and use of placebos (14). In a 
study by Applebaum et al (33) involving subjects of 
four psychiatric clinical trials in the US, 40% stated 
that they had been assigned to treatment arm based 
on their therapeutic needs and 44% did not recognise 
the use of placebo. Krosin et al (9) in their study in 
Mali reported that 74% of the participants did not 
understand that they were enrolled in an investigation 
and not receiving therapy. Many research ﬁndings 
suggest that personal beneﬁts is the major motive for 
participating in clinical trials even when they hold 
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little prospect of beneﬁt (34,35).  When the expected 
results are not realised the backlash can be serious 
leading to withdrawal from the study or resentment 
and anger towards the research team.
 The disease condition and its perceived or 
known prognosis such as cancer and HIV/AIDS may 
impact on study subject’s therapeutic misconception. 
Therapeutic misconception is considered to be widely 
spread globally and fairly common in clinical trials 
(14). However, it has greater implications on the 
informed consent process in clinical trials conducted 
within SSA such as those on HIV/AIDS, which are 
currently quite common, as participants may enroll 
expecting to get full protection or cure of the infection, 
as we have witnessed in some of the HIV prevention 
trials in the region.
iv) Disease condition and severity and its impact on 
informed consent:   Each clinical trial focuses on a 
speciﬁc health condition. It may be aimed at testing a 
preventive strategy such as a vaccine or prophylactic 
treatment or comparing the efﬁcacy and safety of a 
new drug or drug combinations or treatment approach 
to a standard one or placebo. Study subjects in 
preventive studies are healthy individuals whereas 
those in treatment trials are patients with varying 
degrees of severity of the condition. 
 It is postulated that a subject with an immediate 
life-threatening disease and no therapeutic alternative 
might retain less from investigators’ disclosure 
than would a subject with less severe disease or 
healthy volunteers. Likewise patients with life-
threatening conditions are less autonomous than 
healthy volunteers in their decision-making. Their 
motivation for participating in the trial is cure of their 
health condition and may therefore consent without 
considering the risks involved (34).
 Schaeffer et al (34) in their study in the US found 
that healthy volunteers retained information the best 
while severely ill patients retained the least. Likewise 
the sick reported that the informed consent document 
did not have an effect on their decision to participate 
in the trial.  Individuals with serious health conditions 
like cancer and HIV/AIDS may enroll in clinical 
trials with goals that are at variance with the goals 
of the research protocols. The consent document is 
rated as less useful or relevant by study subjects 
with advanced disease conditions. They have poor 
retention of disclosed information on risks perhaps 
due to denial of unpleasant realities, or they want 
to avoid disturbing thoughts associated with risk 
information.
 It is not clear whether the nature of the disease 
has an inﬂuence on the informed consent process. 
However cognizant of the foregoing, it is very likely 
that conditions like cancer and HIV/AIDS have 
similar impact as severe illness. That being the case, 
and considering the fact that majority of HIV/AIDS 
related clinical trials are being conducted in SSA 
because of the high prevalence and incidence, this 
may have great impact on the subjects consent for 
enrollment into the studies. They may be too eager 
to append their signatures on the informed consent 
forms without really understanding what they are 
consenting to. The HIV/AIDS epidemic has raised 
ethical concerns not previously envisaged. In some 
instances people living with HIV/AIDS have claimed 
a right to access to clinical research with the perceived 
notion of cure! When participants in a trial one of 
us was involved in were asked why they enrolled, 
one of the main reasons was that they expected full 
protection against HIV infection.
v) Participants’ remuneration: Renumerating 
research study subjects is a thorny research ethics 
issue. Most international and national guidelines 
on research ethics warn against inducement of 
subjects to participate, but do not explicitly say 
what should be done. The CIOMS (1993) provide the 
most comprehensive guidelines on this issue. While 
discouraging undue inducement of subjects, they 
stipulate that subjects may be paid for inconvenience 
and time spent and be reimbursed expenses incurred 
in connection with their participation in the research. 
They may also receive free medical services (5). There 
are different views though regarding remuneration 
of study subjects (36). Some regard participation as 
a social responsibility deserving no payment but 
recognition for the time and efforts of participants 
(36). Others recommend wage payment based on 
hourly rate for unskilled workers (37). A few ethics 
committees, such as that of South Africa, have 
speciﬁed the actual amount to be paid to subjects in 
clinical trials (11).  While some participants consider 
this appropriate, others feel it is too much or too little 
(38, 39).
 In a number of clinical trials in SSA especially 
those involving children on HIV/AIDS or malaria 
in pregnancy, the subjects get other material beneﬁts 
such as supplementary/complimentary feeds, 
mosquito nets, baby clothes, free treatment of other 
health problems. Likewise the study subjects get 
better care during the trial which they would not 
get in routine medical care. Their hospital bills e.g. 
for accommodation, laboratory tests and drugs are 
paid for by the research. Whereas these are not direct 
payments to study subjects they are regarded as such 
and may also motivate a family or an individual to 
participate in a study.
  Payment of study subjects is contentious 
especially in the context of developing countries. 
Money means different things to different people. 
It is not clear though how much money constitutes 
undue inducement (39). The Belmont Report states 
that undue inﬂuence occurs through an offer of 
an excessive unwanted inappropriate or improper 
reward or other overtures in order to obtain 
compliance (3). Such overtures may compromise the 
informed consent process and scientiﬁc validity of a 
clinical trial (36-39). Whereas the CIOMS guidelines 
state that the study subjects may also receive free 
medical services (5), it does not specify whether these 
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are related to the health condition under study or any! 
The line between “fair compensation” and “undue 
inducement” is often difﬁcult to determine.
 Whereas it is necessary to pay study participants 
for their inconvenience and time spent and effort, as 
well as reimburse expenses such as transport costs, 
ﬁnancial compensation is an important reason for 
many people’s participation in clinical trials. This 
is particularly so in SSA where majority of potential 
study subjects are poor and have no deﬁnite means 
of ﬁnancial sources. Monetary compensation and 
gifts such as those mentioned above may exert undue 
inducement to participate. This will undoubtedly 
compromise their decision-making process or 
willingness to explore the risks and beneﬁts of the 
study before enrolling. 
vi) Social and cultural factors:  Majority of clinical 
trial protocols are written in either English or French 
depending on the originator and/or sponsor as 
well as the host country in which the study will be 
conducted. The informed consent documents as well 
as related information sheets are translated into the 
host country’s  national language and then in some 
cases to the local community language or dialect. 
The main concern in this process is the fact that some 
dialects such as the Bambara in West Africa do not 
have written form. Secondly some words do not have 
direct translation in local languages or dialects. Good 
examples are randomisation, placebo, and clinical 
trial. In translating these words the meaning may be 
distorted. While trying to explain what one word in 
a foreign language means in a local language it may 
require a whole sentence of paragraph, making the 
document too long and not user-friendly. Thirdly, due 
to the low literacy levels in SSA especially among the 
rural majority, who must be included in clinical trials 
conducted within the countries for them to be truly 
representative, the potential subjects may not be able 
to read and understand what they are consenting to. 
For the educationally disadvantaged the researchers 
may read out for them and just ask them to append 
their signatures or thumb-prints as a sign that they 
have understood what the study entails and their 
rights as we observed in one trial. In such cases the 
consent cannot be said to be truly informed and/or 
truly voluntary!.
 The same is true regarding poor patients seeking 
medical attention who are categorised as vulnerable 
to exploitation by researchers (12). Due to their 
social status, they may not ask too many questions 
or may relinquish their autonomy to the research 
team on the assumption that they know what is in 
their best interest. By signing the consent form, some 
participants may feel that it is a binding contract and 
therefore contradict the concept of voluntarism and 
right to withdraw even when they may have side 
effects. Due to previous experiences with signing 
documents, some participants may decide not to 
participate.
 The issue of culture and informed consent process 
especially for the developing countries has been the 
subject of recent scientiﬁc research and publications 
(40, 41). There are concerns regarding consenting for 
minors, adolescents and female subjects in particular. 
We have in the course of our participation in clinical 
trials in various parts of SSA, seen cases where a 
mother who is a legal guardian of a child consents 
for her child to be enrolled in a clinical trial, only for 
the father to withdraw the consent and rebuke her 
and the research team because he was not consulted, 
or parents-in-law of the woman in patrilineal or 
woman’s parents, brother or uncle in matrilineal 
societies may have to be consulted to give their nod 
before one can consent. It becomes confusing in such 
situations as to who really is supposed to give consent 
for a child to be enrolled in a children’s clinical trial. 
It is also not clear who should give consent in cases 
of adolescent females, even when already married 
and/or are mothers themselves. Can she be regarded 
as an adult by virtue of her marital status or is she 
still a minor legally? What is more disturbing is that 
the same adolescent mother is a legal guardian for 
her child and can give consent for medical care! The 
law and research ethics are silent on this issue! 
 In most societies in Africa a married woman 
needs her husband’s endorsement or approval to 
receive certain types of health care services such 
as contraception and surgery. For clinical trials 
on reproductive issues e.g. vaginal microbicides, 
condoms, with sexual behaviour as one of the 
requisites for assessing success or failure of the 
study, cooperation of the two individuals is essential. 
The same can be said of trials which require sexual 
abstinence or which may impact of sexual performance 
or enjoyment thereof such as male circumcision or 
condom use. In such cases whose consent is required; 
both or the subject’s and who is the subject in this case? 
Whose autonomy are we talking about in this case? 
What happens when the spouse is not consulted in 
advance? In one study involving vaginal gel, which 
made the vagina wetter than expected in a society 
which prefers dry sex, a number of the participants 
had to withdraw as their husbands threatened them 
with divorce and some were abandoned or beaten. In 
yet another study testing acceptability and use of the 
female condom in reducing STI’s the study had to be 
abandoned because of refusal by the male partners 
of the subjects.
 It is argued that local community opinion on 
pertinent beliefs and practices should inform ethical 
decision-making in health research. In some cultures a 
woman can not be alone with a man even in the health 
care facility. Another woman such as one’s mother, 
sister or mother-in-law must be with her constantly. 
In a study one of us was involved in, which had 
pregnancy as an exclusion criterion, required asking 
potential subjects about menstrual history, their 
sexual behaviour and contraceptive use, and when 
in doubt to do a pregnancy test. There was strong 
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resistance from the community as it was considered 
taboo to ask girls below certain age about sex and do 
pregnancy tests. There are problems in such situations 
during the consenting process since there will not be 
any conﬁdentiality. Health care providers will have 
a difﬁcult task when asking relevant but sensitive 
questions or when disclosing results to the subject. 
The subjects may hold back vital information on 
questions which would inﬂuence their eligibility for 
the study. Dickens et al (30) compare patient-physician 
relationship in disclosure of secrets which they would 
not even disclose to their spouses, or close relatives, to 
that of a congregant-priest in religious confession. 
 The informed consent as it is understood derives 
mainly from the western notion of individuality. It refers 
to the individual rights and autonomy. However in 
some countries in the developing world there is more of 
communalism where the individual considers himself/
herself as part of the larger society and whatever s/he 
does is for the good of the society (26). The procedures 
of disclosure and consent norms as envisaged in the 
western model may not work. In some instances the 
community through its leaders has to give a nod for 
its members to be involved in any clinical trial as it 
is seen to infringe on its cultural values as we have 
experienced in some of the trials we have been involved. 
The members can only consent to participate in clinical 
trials with approval of the community elders. When this 
happens we wonder whose rights are being protected 
the individual’s or that of the community? There are 
also issues with deﬁnition of the “community” in such 
cases.  Moodley (26) avers that concepts such as risk-
beneﬁt ratio and fair treatment of trial participants may 
be interpreted differently in traditional rural African 
communities. It has been argued that in some cultural 
contexts it may be appropriate to obtain agreement 
from a particular community or assent from a senior 
family member, before any prospective participant in 
research is approached. In either case the individual’s 
consent must always be obtained 
DISCUSSION
Informed consent is a critical component of clinical 
trial procedures. It is a continuous and interactive 
process that enables an individual to voluntarily 
decide whether to participate in a research study or not 
as well allows one to withdraw at any time. It is meant 
to ensure and protect the individual’s autonomy, 
dignity and rights. Truly informed and voluntary 
consent is necessary for the results of a clinical trial to 
be credible and reliable. The subjects must therefore 
receive sufﬁcient and correct information on the 
study itself and the consent process. There should 
be effective communication in an ongoing manner 
throughout the study period to ensure high level of 
comprehension and retention of disclosures (2,4).
 Studies in the region and elsewhere have shown 
that there are major challenges in achieving truly 
informed and voluntary consent for clinical trials (7, 9 
- 13, 25, 36, 42 ). Whereas these challenges are global, 
they are more pertinent in SSA and other parts of 
the developing world which are increasingly seeing 
more clinical trials especially with the HIV/AIDS 
pandemic, with its weak health care delivery systems 
and administrative capabilities as well as low literacy 
and high poverty levels.
 The ethics committees and institutional review 
boards in some countries in Africa which are necessary 
to ensure protection of the safety, rights and well-being 
of study subjects, are weak, ill-equipped or non-
existent in some cases. They often approve protocols 
without even reviewing them or understanding the 
contents therein, because of limited knowledge of 
research and scientiﬁc terms (19-21).
 As majority of clinical trials conducted in SSA 
originate and are sponsored by manufacturers or 
organisations based in industrialised countries, the 
members of the research team who are often poorly 
paid employees of public institutions by international 
standards, may be compromised to carry out trials for 
their own beneﬁts disregarding the rights and safety 
of the participants. This must be guarded against at all 
cost. Likewise the main researchers i.e. the principal 
investigators may be foreigners who have little or no 
knowledge of the host country’s social, cultural and 
economic contexts and have no personal interest in 
the health care of the study population. They may 
disregard important ethical considerations which may 
infringe on the rights and safety of the subjects. As 
stated by Doyal (43) “when human autonomy and 
dignity are at stake, the cost of scientiﬁc progress is 
too high”. 
 Comprehension of disclosed information is 
essential for informed decision making. Tobias et al 
(29) believe that informed consent can some times be 
needlessly cruel by the contents therein and its length. 
Montgomery et al (44) state that the disclosures should 
use tactful and through a sympathetic dialogue so that 
potential subjects understand the difﬁcult scientiﬁc 
or medical terminologies. For the educationally 
disadvantaged rural and peri-urban residents of SSA 
this is a major challenge. The research team needs to 
not only be aware of that but also ensure that each 
participant understands the requisite information 
through probing questions and repetition of the 
disclosures and responding to subjects questions 
in a sympathetic manner throughout the period of 
study.
 Whereas therapeutic misconception is a global 
phenomenon, it is more acute in SSA due to its 
uniqueness. The clinical investigators need to be 
aware of this possibility and ensure they minimise 
it as much as possible, by providing requisite 
information in such a way that allows subjects to 
make the distinction between research and routine 
medical care. They should also ask probing questions 
regarding the reasons for participating.
 Whereas appropriate compensation of 
participants for their efforts and time as well as 
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reimbursement of expenses related to the study 
is acceptable, there are no guidelines on what is 
appropriate and acceptable level (36, 38, 39). Secondly 
what may be appropriate or adequate in one place and 
for one trial may either be too much or too little for 
another. Other materials given either as gifts or part 
of the study such as infant feeds, mosquito nets, baby 
clothes, may be considered an “undue inducements” 
especially for poor communities. There is therefore 
need for national guidelines taking cognisance of 
local situations.
 Although there is no consensus on how clinical 
trial protocols and informed consent should be treated 
in different social and cultural contexts, it is wise for 
originators of international clinical trials to be aware 
of local social and cultural norms and values when 
designing trials for developing countries to avoid 
conﬂict with local communities as we have witnessed 
in some of the trials we have been involved in. At 
times it is advantageous to work with rather than 
through local communities!
 Subjects’ consent to treatment is basic ethical 
and legal pre-condition to conscientious medical 
practice and the ethical principal of respect for 
person’s autonomy requires that they understand the 
available treatment options among which they may 
choose. In clinical trials the subjects have options to 
participate or not as well as to drop out at any time. 
The decision to do either can only be genuine and 
valid if it is based on adequate information. The 
major challenge is how much information should be 
disclosed to be considered “enough” for appropriate 
decision, but at the same time not so much as to coerce 
or frighten subjects either from participating or into 
compliance. 
 The mere formulation and publication of ethical 
guidelines for biomedical research involving human 
subjects is not enough to ensure protection and safety 
of participants in clinical trials. They do however 
draw the attention of investigators, sponsors and 
ethical review committees to the need to consider 
carefully the ethical implications of research protocols 
and conduct of research and the need to ensure high 
scientiﬁc and ethical standards of research.
RECOMMENDATIONS 
Well-conducted randomised clinical trials form 
the most influential basis of today’s evidence-
based medical practice.  Cognisant of increasing 
internationalisation of clinical trials and that for 
some the developing world will be its best study 
sites, and in order for the results thereof to be of 
comparable international standards, there is need to 
ensure that the internationally accepted good clinical 
practice is upheld. Informed consent must be truly 
informed and truly voluntary. To help achieve that 
we recommend that:
(i) There is need for national guidelines on research 
including ethics review, compensation of 
subjects, requirements for research investigators 
and facilities and Ethics Committees/IRB’s, as 
well as budgetary allocation. 
(ii) Local bioethics capacity should be developed 
and strengthened. The EC and IRB should have 
appropriate training, funding and support. 
Organisations funding and conducting clinical 
trials and other research studies in SSA should 
contribute to the national research budgets and 
the funds may be used for this. At the same time 
each organisation could budget for training of 
EC/IRB which could be organised prior to studies 
or on a regular basis. In particular, non-medical 
members of the ethics committees need to be 
given adequate training on their responsibilities 
and their value within the committee.
(iii) The pre-service curricula of health care 
professionals such as doctors, nurses, clinical 
ofﬁcers etc, should include training on research 
ethics and methodology as well as interpersonal 
communication. Before starting a research study 
the research team should undergo training and 
certiﬁcation on good clinical practice as a matter 
of routine.
(iv) The research team should dedicate one of its 
member or a neutral educator to spend time 
talking one-on-one with study subjects to ensure 
they understand the requisite information.
(v) Evaluation of informed consent process and 
procedures should be an integral part of every 
clinical trial so as to identify issues that need to 
be addressed. This should be included in the 
protocol and budgeted for.
(vi) There is need for more regionally and nationally 
relevant research studies on various aspects of 
the informed consent which will provide vital 
information to help the process in future trials. 
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